EHRA Premium Access

Controversies in channelopathy

Event: EHRA 2018
Topic: Ventricular Arrhythmias and SCD - Pathophysiology and Mechanisms - Ion Channel Disorders
Session type: Debate Session
Date: 20 March 2018
Time: 08:30 - 10:00

Congress Session

12 presentations in this session

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - PRO

Speaker: Professor V. Probst (Nantes, FR)
Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - CON

Speaker: Professor S. Viskin (Tel Aviv, IL)
Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal PRO

Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal CON

Thumbnail

Chairperson conclusion & Closing question

Thumbnail

Long QT Syndrome is not a contraindication to competitive sport - PRO

Speaker: Doctor M. Ackerman (Rochester, US)
Thumbnail

Long QT Syndrome is not a contraindication to competitive sport - CON

Speaker: Professor F. Schnell (Rennes, FR)
Thumbnail

Long QT Syndrome is not a contraindication to competitive sport - Rebuttal PRO

Thumbnail

4 speakers from this session

Professor Vincent Probst

University Hospital of Nantes - Hospital Guillaume & Rene Laennec, Nantes (France)
7 presentations
0 follower

Professor Samuel Viskin

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)
7 presentations
0 follower

Doctor Michael Ackerman

Mayo Clinic, Rochester (United States of America)
5 presentations
0 follower

Professor Frederic Schnell

University Hospital of Rennes - Hospital Pontchaillou, Department of Cardiology and Vascular Disease, Rennes (France)
9 presentations
0 follower

This platform is supported by

logo Novo Nordisk